INSIGHT. A new generation of predictive health is emerging at the intersection of artificial intelligence and life science. Researchers at the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ) and the University of Copenhagen have developed Delphi-2M, a generative AI model that predicts the risk of developing
INSIGHT. Crossing the blood-brain barrier has long been one of the greatest challenges in drug development. Now we’re seeing technological breakthroughs that open the door for new treatments of neurodegenerative diseases, an area with great medical need and growing investment interest. A smart protection, but also a barrier to treatment
PRESS RELEASE. Sciety has strengthened the board of its portfolio company PeptiSystems by appointing Nick Roelofs – a strategic addition that significantly enhances the company’s ability to scale global sales and build strong industrial partnerships within advanced pharmaceutical manufacturing. The appointment is part of Sciety’s broader strategy to actively contribute specialist
PRESS RELEASE. Sciety’s portfolio company Pharmability (fd TIRmed) has strengthened its board with the appointment of Peder Walberg – a strategic addition as the company advances the development of a promising new treatment for atopic dermatitis (eczema). The appointment is the result of a targeted recruitment process carried out in close
INSIGHT. Cardiac arrest can strike anyone, at any time – and every minute is crucial for survival. Although early cardiopulmonary resuscitation (CPR) and defibrillation can dramatically increase the chances of survival, mortality rates remain high. Let us take a closer look at proven methods that save lives, as well as new
INSIGHT. The life science sector is evolving rapidly and remains an attractive field for investors. New technologies are enabling treatments, diagnostics, and medical devices that were once unimaginable. Scientific breakthroughs and innovative companies are driving the industry forward. But as an investor, how can you identify the most promising companies to invest
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.